- 1 Disease Entity
- 2 Diagnosis
- 3 Management
- 4 Additional Resources
- 5 References
Sebaceous carcinoma is a rare, highly malignant, and potentially lethal tumor of the skin, which most commonly occurs in the eyelid. The neoplasm arises from sebaceous glands, such as those of the meibomian glands in the tarsus, the Zeis glands of the eyelashes, the caruncle, and the skin of the eyebrow. The lesion occurs more often in the upper eyelid, most likely due to the presence of a greater number of meibomian glands (~50 glands in upper eyelids, ~25 in lower).
Sebaceous carcinoma can also occur in other body areas in 25% of cases including other areas of the head and neck and other areas of skin with hair, even genitalia .
Muir-Torre Syndrome (MTS) is an important consideration when a patient is diagnosed with sebaceous carcinoma. MTS is an autosomal dominant condition of sebaceous tumors associated with gastrointestinal, endometrial, urologic tumors (without any predisposing factors). The sebaceous tumors included in this syndrome are: sebaceous adenoma, basal cell epithelioma with sebaceous differentiation, sebaceous carcinoma. Cohen et al. reported that 24% of 120 MTS patients had sebaceous carcinoma. The sebaceous carcinomas in MTS are less aggressive and less likely to metastasize than solitary sebaceous carcinoma .
A review of 5504 eyelid skin tumors by a single ophthalmologist in Switzerland from 1989-2007 showed the following:
|Squamous cell papilloma (26%)|
|Seborrheic keratosis (21%)|
|Melanocytic nevus (20%)|
|(chalazia not included in study, #3340)|
|Basal cell carcinoma (86%)|
|Squamous cell carcinoma (7%)|
|Sebaceous carcinoma (3%)|
Of note, of the 29 total patients with sebaceous carcinoma (29/5504 = 0.5%), only 1 was diagnosed clinically. 
The condition occurs more frequently in females. The upper eyelid accounts for the majority of cases. Older age is risk factor, as the reported median age at presentation has ranged between 57 and 72 years. However, tumors can arise in younger individuals who have been treated with periocular irradiation. The tumor has a higher incidence in Asia compared with North America. 
A high index of suspicion is critical for the diagnosis of sebaceous carcinoma. Clinical suspicion should be higher when a patient has an atypical presentation of a typical diagnosis. For example: atypical or recurrent chalazia in the upper lid, yellow thickening of the eyelid, keratoconjunctivitis or blepharoconjunctivitis unresponsive to treatment, or persistent blepharitis.
Sebaceous carcinoma is yellow in appearance (from the lipid within the neoplastic cells). It arises at the sebaceous glands, usually at the lid margin and can extend to the palpebral conjunctiva. Therefore, it is important to evert the lid, as seen in the third picture below.
Sebaceous Carcinoma is one of the great masqueraders--it can mimic other, more benign lesions. It can mimic chalazia, chronic blepharitis, basal cell carcinoma, squamous cell carcinoma, superior limbic keratoconjunctivits, ocular cicatricial pemphigoid.
The clinical diagnosis of sebaceous carcinoma is difficult. A study of 4 oculoplastic ophthalmologists in Canada examined 358 cases of periocular lesions--of which 2 were sebaceous carcinoma. The clinical diagnosis of these two lesions were: basal cell carcinoma and a vague diagnosis (e.g. lesion or mass). 
The sebaceous carcinoma mass is usually painless.
One of the hallmark features of sebaceous carcinoma is pagetoid spread--spreading of malignant cells to epithelium that appears to be separate from main tumor. Therefore, it is important to obtain a wide excisional biopsy of the primary lesion and map biopsies of the conjunctiva (including the palpebral conjunctiva in both lids and 4 quadrants of the bulbar conjunctiva). It is important to mark the margins when submitting a specimen to pathology. Communicate with the pathologist the importance of evaluating the margins for disease.
The histopathology varies depending on the differentiation of the tumor. In well differentiated lesions, there is a lobular arrangement and vacuolization of the cytoplasm cells centrally.
Cells present will include sebaceous and undifferentiated cells. There may be variation in nucleus shape and size with high mitotic activity indicated by mitotic figures. Special stains can be used to help distinguish sebaceous carcinoma: oil red-O, Sudan IV, epithelial membrane antigen, Leu-m1 immunostains. 
Below are examples of sebaceous carcinoma. The first image shows an eyelid margin with normal sebaceous glands at the inferior margin, the invasive sebaceous carcinoma, and a hair follicle in between. The 2nd and 3rd images are high power images of the carcinoma (with mitotic figures in deep purple) and normal sebaceous glands.
The differential diagnosis includes any benign or malignant condition of the eyelid skin, including:
- Seborrheic keratosis
- Actinic keratosis
- Squamous papilloma
- Basal cell carcinoma
- Squamous cell carcinoma
- Malignant melanoma
- Merkel cell tumor
The mainstay of treatment is surgical excision. It is important to ensure a full thickness specimen, obtain map biopsies of the conjunctiva. If invasive, orbital exeteration may be indicated. Staging is assessed using the TNM definitions as provided by the American Joint Committee on Cancer recommendations. Sentinel lymph node biopsies can be obtained. According to the AJCC "it seems reasonable to recommend sentinel lymph node biopsy or at least strict regional lymph node surveillance for patients with sebaceous carcinoma of the eyelid who have T category of T2b or worse or tumors of 10mm or more in greatest dimension." 
Wide local excision
Exenteration for large, deeply invasive lesions, or significant bulbar conjunctival involvement.
Sentinel lymph node biopsies for Stage T2b or worse. (T2b: tumor >10mm, but not >20mm in greatest dimension; or, involves full thickness eyelid). 
Sebaceous carcinoma can recur in up to 33% of the cases.
T category of T3a or worse correlated with distant mets and death. In the AJCC's study of 50 consecutive patients with sebaceous carcinoma, 5 (10%) died. No tumors <12mm were associated with distant mets or death. 
- American Academy of Ophthalmology. Ocular Pathology/Oncology: Sebaceous carcinoma Practicing Ophthalmologists Learning System, 2017 - 2019 San Francisco: American Academy of Ophthalmology, 2017.
- Buitrago, William and Aaron Joseph. Sebaceous carcinoma: the great masquerader. Dermatologic Therapy. Vol 21, 2008, 459-466.
- Cohen PR, Kohn SR, Kurzrock R. Association of sebaceous gland tumors and internal malignancy: the Muir-Torre syndrome. Am J Med 1991: 90: 606-613.
- Deprez, Manuel and Uffer, Sylvie. Clinicopathological Features of Eyelid Skin Tumors. A Retrospective Study of 5504 Cases and Review of Literature. Am J Dermatopathol 2009; 31:256-262.
- Hillson, Harvey, Hurwitz, Lie, Oestreicher, Pashby. Sensitivity and specificity of the diagnosis of periocular lesions by oculoplastic surgeons. Can J Ophthalmol 1998;33:377-83.
- Esmaeli, Bita et al. American Joint Committee on Cancer T Category for Eyelid Sebaceous Carcinoma Correlates with Nodal Metastasis and Survival. Ophthalmology 2012;119:1078-1082.
- Orbit, Eyelids, and Lacrimal System, Section 7. Basic and Clinical Science Course. San Francisco: American Academy of Ophthalmology; 2009.
- Ophthalmic Pathology and Intraocular Tumors, Section 4. Basic and Clinical Science Course. San Francisco: American Academy of Ophthalmology; 2009.